Protagonist Therapeutics Inc (PTGX) Stock Analysis

Protagonist Therapeutics Inc (PTGX) is a publicly traded company in the HEALTHCARE sector. It trades at $93.23, carries a market capitalization of $6.10B. This page summarizes the public market data, fundamentals, and frequently asked questions for PTGX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Protagonist Therapeutics Inc currently has a Bullish sentiment score of 0.31.

About Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc. (PTGX) is a clinical-stage biopharmaceutical company focused on developing innovative peptide-based therapies aimed at addressing significant unmet medical needs, particularly in gastrointestinal disorders and hematological diseases. Leveraging its proprietary peptide technology platform, Protagonist is advancing a robust pipeline of therapeutic candidates designed to enhance patient outcomes. Based in Newark, California, the company is strategically positioned ...

GNG Research Analysis

GNG Research scores Protagonist Therapeutics Inc (PTGX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for PTGX.

Frequently Asked Questions

Does PTGX pay dividends?

Protagonist Therapeutics Inc (PTGX) does not currently pay a regular dividend.

What is PTGX's market cap?

Protagonist Therapeutics Inc (PTGX) has a market capitalization of $6.10B with a current stock price of $93.23.